Non-CYP-metabolism. However side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Bleomycin sulphat is an antineoplastic antibiotic consisting of a mixture of glucopeptides isolated from Streptomyces verticillusor.

Bleomycin is used in combination with other forms of chemotherapy in the treatment of epithelial carinomas at different locations, malignant lymphomass, testistumors, malignant pleura effusions. It is administered intravenously or as intramuscular injection. Common adverse reactions of bleomycin that can be confused with an acute porphyric attack are nausea and vomiting. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Probably not significant.

Bleomycin is primarily metabolised by enzymatic degradation, 60-70% is excreted in unchanged form in urine. No reports of CYP interactions. Not listed as CYP substrate, inhibitor or inducer. Baumhakel (2002) found no inhibitory effect of bleomycin on CYP3A4.

Used uneventfully in the treatment of testicular cancer in man with AIP. (Arbus, 1981).